Interferon gamma


Generic Medicine Info
Indications and Dosage
Subcutaneous
Chronic granulomatous disease, Malignant osteopetrosis
Adult: Patient with a BSA >0.5 m2: 50 mcg/m2 (1 million units/m2) 3 times weekly. Patient with a BSA ≤0.5 m2: 1.5 mcg/kg 3 times weekly.
Child: Same as adult dose.
Contraindications
Hypersensitivity to interferon gamma.
Special Precautions
Patient with impaired CNS function or history of seizures, myelosuppression, CV disease (e.g. ischaemia, heart failure, arrhythmia). Severe renal and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Hypersensitivity reaction, flu-like symptoms (e.g. fever, headache, chills, myalgia, fatigue), decreased mental status, gait disturbance, dizziness, neutropenia, thrombocytopenia, raised AST or ALT.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain.
General disorders and administration site conditions: Injection site pain and erythema.
Musculoskeletal and connective tissue disorders: Arthralgia, back pain.
Psychiatric disorders: Depression.
Skin and subcutaneous tissue disorders: Rash.
Patient Counseling Information
This medicine may cause fatigue, convulsion, confusional state, disorientation or hallucinations, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor CBC with differential, platelets, electrolytes, urinalysis, BUN, and creatinine prior to therapy and at 3 month-intervals; LFTs monthly in children <1 year.
Drug Interactions
Enhanced adverse effects of zidovudine. May prolong the half-lives of drugs that are metabolised by the CYP-450 system.
Action
Description: Interferon gamma is a cytokine with immunomodulating and antiviral effects that increases macrophage cytotoxicity by enhancing the respiratory burst via generation of toxic oxygen metabolites, which mediate the killing of intracellular microorganisms. It increases HLA-DR expression and augments Fc receptors expression, thereby causing an increased antibody-dependent cell mediated cytotoxicity.
Synonym: interferon gamma-1b.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: Approx 7 hours.
Excretion: Elimination half-life: Approx 6 hours.
Storage
Store between 2-8°C. Do not freeze.
MIMS Class
ATC Classification
L03AB03 - interferon gamma ; Belongs to the class of interferons. Used as immunostimulants.
References
Actimmune (Horizon Therapeutics USA, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 12/08/2020.

Anon. Interferon Gamma-1b. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/08/2020.

Anon. Interferon Gamma. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 12/08/2020.

Buckingham R (ed). Interferon Gamma. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/08/2020.

Immukin Solution for Injection (Clinigen Healthcare Limited). MHRA. https://products.mhra.gov.uk/. Accessed 13/08/2020.

Disclaimer: This information is independently developed by MIMS based on Interferon gamma from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in